GigaGen is working on a recombinant polyclonal antibody, recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG), as a Covid-19 treatment.
The therapy reproduces whole antibody repertoires of recovered patients, including antibodies that block further replication of the novel coronavirus.
GigaGen will formulate the antibody for intravenous administration to deliver passive immunity.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData